METABOLIK SINDROMDA KO‘Z TOMIRLARI ENDOTELIYSIDAGI PATOLOGIK O‘ZGARISHLARNI BIOKIMYOVIY MARKERLAR ORQALI BAHOLASH
Keywords:
Kalit so‘zlar: Metabolik sindrom, endotelial disfunktsiya, azot oksidi, endotelin-1, ICAM-1, VCAM-1, E-selectin, mikroangiopatiya, ko‘z tomirlari, biokimyoviy markerlar, oftalmoskopiya.Abstract
Annotatsiya. Ushbu maqolada metabolik sindromga (MS) chalingan
bemorlarda ko‘z tomirlari endoteliysida yuzaga keladigan patologik o‘zgarishlarni
baholashda biokimyoviy markerlarning ahamiyati o‘rganildi. Tadqiqotga 12 nafar MS
tashxisi qo‘yilgan bemor jalb qilindi. Bemorlarning qon zardobida azot oksidi (NO),
endotelin-1, VCAM-1, ICAM-1 va E-selectin darajalari aniqlandi hamda
oftalmoskopiya orqali ko‘z tomirlaridagi mikroangiopatik o‘zgarishlar baholandi.
Natijalar NO darajasining pasayishi va boshqa markerlarning oshishi endotelial
disfunktsiyaning kuchayganini ko‘rsatdi. Bu holat mikrosirkulyatsiyaning buzilishi,
ko‘z tomirlari devorlarining yallig‘lanishi va o‘tkazuvchanligining ortishi bilan bog‘liq
ekanligi aniqlandi. Biokimyoviy markerlar MSda ko‘z mikrotomirlari holatini
baholashda muhim diagnostik vosita sifatida taklif qilinadi.
References
Adabiyotlar:
1. Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin,
B. A., ... & Costa, F. (2005). Diagnosis and management of the metabolic syndrome:
an American Heart Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation, 112(17), 2735–2752.
2. Davignon, J., & Ganz, P. (2004). Role of endothelial dysfunction in atherosclerosis.
Circulation, 109(23_suppl_1), III-27–III-32.
3. Hadi, H. A. R., & Suwaidi, J. A. (2007). Endothelial dysfunction in diabetes
mellitus. Vascular Health and Risk Management, 3(6), 853–876.
4. Huang, A. L., Silver, A. E., & Vita, J. A. (2011). Effects of nitric oxide on vascular
function. Current Opinion in Cardiology, 26(4), 379–383.
5. Kim, J. A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006). Reciprocal
relationships between insulin resistance and endothelial dysfunction. Circulation,
113(15), 1888–1904.
6. Kowluru, R. A., & Chan, P. S. (2007). Oxidative stress and diabetic retinopathy.
Experimental Diabetes Research, 2007, Article ID 43603.
7. Gündüz, A., & Yilmaz, G. (2014). Biomarkers of endothelial dysfunction in
metabolic syndrome. Clinical Chemistry and Laboratory Medicine (CCLM),
52(12), 1707–1713.
8. Wong, T. Y., & Mitchell, P. (2007). The eye in hypertension. The Lancet,
369(9559), 425–435.
9. Poredos, P., & Jezovnik, M. K. (2013). Endothelial dysfunction and cardiovascular
disease. International Angiology, 32(2), 109–116.
10. Böger, R. H. (2004). Association of asymmetric dimethylarginine and endothelial
dysfunction. Clinical Chemistry and Laboratory Medicine, 41(11), 1467–1472.
11. Schalkwijk, C. G., & Stehouwer, C. D. A. (2005). Vascular complications in
diabetes mellitus: the role of endothelial dysfunction. Clinical Science, 109(2), 143–
159.
12. Lerman, A., & Zeiher, A. M. (2005). Endothelial function: Cardiac events.
Circulation, 111(3), 363–368.
